Skip to main content
Top
Published in: Journal of Gastroenterology 9/2009

01-09-2009 | Original Article—Alimentary Tract

Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy

Authors: Masayuki Nakayama, Ryuichi Iwakiri, Megumi Hara, Hibiki Ootani, Ryo Shimoda, Seiji Tsunada, Hiroyuki Sakata, Kazuma Fujimoto

Published in: Journal of Gastroenterology | Issue 9/2009

Login to get access

Abstract

Objective

This study aimed to clarify the current situation of bleeding peptic ulcers and examined the temporal changes in the pathogenic mechanisms requiring emergency endoscopy.

Patients and methods

Study subjects were 285 bleeding peptic ulcer patients who received emergency endoscopy in Saga Medical School Hospital between 2000 and 2007. The ratios of H. pylori infection, NSAID use and low-dose aspirin use were analyzed for differences between the two periods by chi-square test. Logistic regression analysis was used to investigate factors such as patient characteristics that influenced the differences between each period.

Results

A total of 221 (77.5%) patients were identified as H. pylori-positive. One hundred (35.1%) patients reported a history of NSAID use within 4 weeks. Among NSAID users, 41 patients received daily low-dose aspirin. One hundred forty-one patients had bleeding ulcers in 2000–2003 and 144 patients in 2004–2007. The odds ratio (OR) between the periods was 0.806 (95% CI, 0.461–1.409) for H. pylori infection and 1.590 (95% CI, 0.973–2.598) for NSAID usage. In contrast, the proportion of patients who took low-dose aspirin was 9.9% in the first period and 18.8% in the second period, and the difference was statistically significant (OR 2.093; 95% CI, 1.047–4.185). Logistic regression analysis revealed that cardiovascular disease and cerebral vascular disease were associated with aspirin use.

Conclusion

This study indicates that the causes of bleeding ulcers are changing, and the increasing use of low-dose aspirin might become a major cause of bleeding ulcers.
Literature
1.
go back to reference Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994;89:S116–28.PubMed Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994;89:S116–28.PubMed
2.
go back to reference García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–72.PubMedCrossRef García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–72.PubMedCrossRef
3.
go back to reference Slattery J, Warlow CP, Shorrock CJ, Langman MJ. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin—analysis of gastrointestinal bleeding during the UK-TIA trial. Gut. 1995;37:509–11.PubMedCrossRef Slattery J, Warlow CP, Shorrock CJ, Langman MJ. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin—analysis of gastrointestinal bleeding during the UK-TIA trial. Gut. 1995;37:509–11.PubMedCrossRef
4.
go back to reference Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists’ Collaboration. BMJ 1994;308:159–68. Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists’ Collaboration. BMJ 1994;308:159–68.
5.
6.
go back to reference Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2000;324:71–86. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2000;324:71–86.
7.
go back to reference Nishikawa K, Sugiyama T, Kato M, Ishizuka J, Komatsu Y, Kagaya H, et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol. 2000;12:635–40.PubMedCrossRef Nishikawa K, Sugiyama T, Kato M, Ishizuka J, Komatsu Y, Kagaya H, et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol. 2000;12:635–40.PubMedCrossRef
8.
go back to reference Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–6.PubMed Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–6.PubMed
9.
go back to reference Fujisawa T, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol. 1999;94:2094–9.PubMedCrossRef Fujisawa T, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol. 1999;94:2094–9.PubMedCrossRef
10.
go back to reference Takada M, Fukumoto K, Shibakawa M. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs. J Clin Pharm Ther. 2004;29:183–7.PubMedCrossRef Takada M, Fukumoto K, Shibakawa M. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs. J Clin Pharm Ther. 2004;29:183–7.PubMedCrossRef
11.
go back to reference Ootani H, Iwakiri R, Shimoda R, Nakahara S, Amemori S, Fujise T, et al. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol. 2006;41:41–6.PubMedCrossRef Ootani H, Iwakiri R, Shimoda R, Nakahara S, Amemori S, Fujise T, et al. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol. 2006;41:41–6.PubMedCrossRef
12.
go back to reference Kikkawa A, Iwakiri R, Ootani H, Ootani A, Fujise T, Sakata Y, et al. Prevention of the rehaemorrhage of bleeding peptic ulcers: effects of Helicobacter pylori eradication and acid suppression. Aliment Pharmacol Ther. 2005;21(Suppl 2):79–84.PubMedCrossRef Kikkawa A, Iwakiri R, Ootani H, Ootani A, Fujise T, Sakata Y, et al. Prevention of the rehaemorrhage of bleeding peptic ulcers: effects of Helicobacter pylori eradication and acid suppression. Aliment Pharmacol Ther. 2005;21(Suppl 2):79–84.PubMedCrossRef
13.
go back to reference Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749–56.PubMed Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749–56.PubMed
14.
go back to reference Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23:163–73.PubMedCrossRef Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23:163–73.PubMedCrossRef
15.
go back to reference Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–72.PubMedCrossRef Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–72.PubMedCrossRef
16.
go back to reference Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075–8.PubMedCrossRef Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075–8.PubMedCrossRef
17.
go back to reference Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787–96.PubMed Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787–96.PubMed
18.
go back to reference Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257–63.PubMed Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257–63.PubMed
19.
go back to reference Targownik LE, Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993–2003. Clin Gastroenterol Hepatol. 2006;4:1459–66.PubMedCrossRef Targownik LE, Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993–2003. Clin Gastroenterol Hepatol. 2006;4:1459–66.PubMedCrossRef
20.
go back to reference Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;12:1621–6.CrossRef Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;12:1621–6.CrossRef
21.
go back to reference de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2000;1:1.CrossRef de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2000;1:1.CrossRef
22.
go back to reference Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–9.PubMedCrossRef Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–9.PubMedCrossRef
23.
go back to reference Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827–30.PubMed Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827–30.PubMed
24.
go back to reference García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563–71.PubMedCrossRef García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563–71.PubMedCrossRef
25.
go back to reference Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–24.PubMed Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–24.PubMed
26.
go back to reference Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin:meta-analysis. BMJ. 2000;321:1183–7.PubMedCrossRef Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin:meta-analysis. BMJ. 2000;321:1183–7.PubMedCrossRef
27.
go back to reference Kang JY, Elders A, Majeed A, Maxwell JD, Bardhan KD. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982–2002. Aliment Pharmacol Ther. 2006;24:65–79.PubMedCrossRef Kang JY, Elders A, Majeed A, Maxwell JD, Bardhan KD. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982–2002. Aliment Pharmacol Ther. 2006;24:65–79.PubMedCrossRef
28.
go back to reference Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006;62:765–72.PubMedCrossRef Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006;62:765–72.PubMedCrossRef
29.
go back to reference Nakashima S, Arai S, Mizuno Y, Yoshino K, Ando S, Nakamura Y, et al. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2005;21(suppl 2):60–6.PubMedCrossRef Nakashima S, Arai S, Mizuno Y, Yoshino K, Ando S, Nakamura Y, et al. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2005;21(suppl 2):60–6.PubMedCrossRef
Metadata
Title
Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy
Authors
Masayuki Nakayama
Ryuichi Iwakiri
Megumi Hara
Hibiki Ootani
Ryo Shimoda
Seiji Tsunada
Hiroyuki Sakata
Kazuma Fujimoto
Publication date
01-09-2009
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 9/2009
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0074-2

Other articles of this Issue 9/2009

Journal of Gastroenterology 9/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.